›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:GALEAS™ Tumor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
NonacusType:
Laboratory Developed Test
Related tests:
GALEAS™ Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumors, allowing clinicians to accurately diagnose cancers and tailor treatments. It combines targeted NGS panels with bespoke bioinformatics for variant calling – the process of detecting differences in genetic sequences that are involved in cancer – and software for analysing the results.
Cancer:
Solid Tumor
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), MSI (Microsatellite instability)
See More ...
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), MSI (Microsatellite instability), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TMB (Tumor Mutational Burden), TMPRSS2 (Transmembrane serine protease 2)
Method:
Next-Generation Sequencing (NGS)
